Loading...
•
Jul 31, 2020
Medtronic Q1 2021 Earnings Report
Medtronic's Q1 2021 financial results reflected a decrease in revenue and EPS due to the impact of the COVID-19 pandemic, but showed signs of recovery with improving procedure volumes and innovative product contributions.
Key Takeaways
Medtronic reported a 13% decrease in Q1 revenue to $6.507 billion, with a GAAP diluted EPS of $0.36 and a non-GAAP diluted EPS of $0.62. The results were impacted by the COVID-19 pandemic, but the company saw a faster than expected recovery with improving procedure volumes.
Q1 revenue decreased by 13% as reported, and approximately 17% organic.
GAAP diluted EPS was $0.36, while non-GAAP diluted EPS was $0.62.
Procedure volumes began to recover around the world.
The company is leveraging its pipeline of innovative products to drive share gains.
Medtronic
Medtronic
Medtronic Revenue by Segment
Medtronic Revenue by Geographic Location
Revenue by Segment
Cardiac Rhythm & HF Revenue
CapyFin.comCoronary & Peripheral Vascular Revenue
CapyFin.comCranial & Spinal Technologies Revenue
CapyFin.comSpecialty Therapies Revenue
CapyFin.comNeuromodulation Revenue
CapyFin.comSurgical & Endoscopy Revenue
CapyFin.comAcute Care & Monitoring Revenue
CapyFin.comDiabetes Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.com Forward Guidance
Given the uncertainty on near-term financial results caused by the COVID-19 pandemic, the company is not providing formal annual or quarterly financial guidance at this time.
Revenue & Expenses
Visualization of income flow from segment revenue to net income